GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » Shiller PE Ratio

Aravive (FRA:VE11) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aravive Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aravive Shiller PE Ratio Historical Data

The historical data trend for Aravive's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Shiller PE Ratio Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aravive's Shiller PE Ratio

For the Biotechnology subindustry, Aravive's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aravive's Shiller PE Ratio falls into.



Aravive Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aravive's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Aravive's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.262/129.8595*129.8595
=0.262

Current CPI (Sep. 2023) = 129.8595.

Aravive Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -1.095 98.326 -1.446
201403 -69.972 99.695 -91.144
201406 -1.590 100.560 -2.053
201409 -2.654 100.428 -3.432
201412 -3.163 99.070 -4.146
201503 -4.380 99.621 -5.709
201506 -3.582 100.684 -4.620
201509 -3.689 100.392 -4.772
201512 -3.801 99.792 -4.946
201603 -4.418 100.470 -5.710
201606 -4.005 101.688 -5.115
201609 -4.918 101.861 -6.270
201612 -3.640 101.863 -4.640
201703 -4.768 102.862 -6.019
201706 -5.554 103.349 -6.979
201709 -7.022 104.136 -8.757
201712 4.411 104.011 5.507
201803 -1.216 105.290 -1.500
201806 -1.404 106.317 -1.715
201809 -0.926 106.507 -1.129
201812 -4.237 105.998 -5.191
201903 -0.372 107.251 -0.450
201906 -0.239 108.070 -0.287
201909 -0.490 108.329 -0.587
201912 -0.315 108.420 -0.377
202003 -0.652 108.902 -0.777
202006 -0.284 108.767 -0.339
202009 -0.560 109.815 -0.662
202012 -0.205 109.897 -0.242
202103 -0.370 111.754 -0.430
202106 -0.291 114.631 -0.330
202109 -0.451 115.734 -0.506
202112 -0.549 117.630 -0.606
202203 -0.563 121.301 -0.603
202206 -0.577 125.017 -0.599
202209 -0.515 125.227 -0.534
202212 -0.434 125.222 -0.450
202303 -0.616 127.348 -0.628
202306 -0.111 128.729 -0.112
202309 0.262 129.860 0.262

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aravive  (FRA:VE11) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aravive Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aravive's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (FRA:VE11) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (FRA:VE11) Headlines

No Headlines